Revelation Biosciences, Inc., (REVB): Price and Financial Metrics


Revelation Biosciences, Inc., (REVB): $0.49

-0.03 (-6.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add REVB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

REVB Stock Price Chart Interactive Chart >

Price chart for REVB

REVB Price/Volume Stats

Current price $0.49 52-week high $11.29
Prev. close $0.52 52-week low $0.40
Day low $0.47 Volume 172,000
Day high $0.55 Avg. volume 1,542,088
50-day MA $0.68 Dividend yield N/A
200-day MA $5.24 Market Cap 7.39M

Revelation Biosciences, Inc., (REVB) Company Bio


Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.


REVB Latest News Stream


Event/Time News Detail
Loading, please wait...

REVB Latest Social Stream


Loading social stream, please wait...

View Full REVB Social Stream

Latest REVB News From Around the Web

Below are the latest news stories about Revelation Biosciences Inc that investors may wish to consider to help them evaluate REVB as an investment opportunity.

Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will present a corporate overview in-person at 10:45 a.m. EST on February 14, 2022 at the BIO CEO & Investor Conference, which is being held at the New York Marriott Ma

Yahoo | February 7, 2022

Revelation Biosciences Raises $7.76 Million in Equity Financing

SAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 1,293,126 shares of Common Stock (“Shares”) at a gross purchas

Yahoo | January 24, 2022

Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection

Top-line data anticipated in the second quarter of 2022SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that the first group of 15 patients have been enrolled and dosed in a Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-

Yahoo | January 20, 2022

Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis

SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced that the first patient has been enrolled and dosed in a Phase 1b clinical study to evaluate the potential utility of REVTx-99 for treating patients with allergic rhinitis and patients with chronic nasal congestion

Yahoo | January 18, 2022

REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company

-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro anti-viral activity assay systems- -Previously announced SPAC merger closes, Revelation Biosciences, Inc. publicly listed on the NASDAQ under symbol REVB- -Revelation to host conference call and webcast at 4:30 p.m. Eastern Time on January 11, 2022. The conference call can be accessed by dialing 877-815-0146 for domestic callers and 631-625-3219 for int

Yahoo | January 13, 2022

Read More 'REVB' Stories Here

REVB Price Returns

1-mo -7.91%
3-mo -79.24%
6-mo -95.19%
1-year N/A
3-year -98.24%
5-year -98.28%
YTD -95.20%
2021 1.49%
2020 -74.36%
2019 37.54%
2018 1.60%
2017 59.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9421 seconds.